[144] Monopar Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

Monopar Therapeutics Inc. (MNPR) – Form 144 filing

An insider intends to sell up to 8,904 common shares through Merrill Lynch on or about 14 July 2025. The proposed sale, valued at $356,160, stems from two stock-option exercises (4,200 options granted 04 Apr 2016 and 4,704 options granted 20 Feb 2017), both to be settled in cash. The filing lists 6,115,214 shares outstanding, making the planned disposition roughly 0.15 % of the float. No other sales were reported in the past three months. The signer affirms no undisclosed material adverse information.

Form 144 is a notice, not an executed trade, but it flags potential insider activity. Given the small fraction of outstanding shares, immediate market impact should be limited; nevertheless, investors often track such filings for sentiment shifts.

Positive

• None.

Negative

• Insider intends to sell 8,904 shares worth $356k, potentially interpreted as negative sentiment despite representing only 0.15 % of float

Insights

Financial Analyst

TL;DR – Small, routine insider sale; unlikely to move MNPR materially.

The 8,904-share sale equals about 0.15 % of shares outstanding and carries a modest $356k market value. With no recent sales and options-exercise origin, this appears to be personal liquidity rather than a strategic divestiture. The limited size suggests neutral impact on trading dynamics, yet continued monitoring of additional filings is prudent.

Corporate Governance Expert

TL;DR – Standard compliance disclosure; governance risk unchanged.

The filer has met Rule 144 disclosure requirements, including attestation of no undisclosed adverse facts. Absence of aggregate sales in the prior three months and the ordinary-course option exercises indicate no governance red flags. Transaction scale is too small to signal board-level concern, so impact is neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch Pierce Fenner & Smith Inc. 110 N. Wacker Drive Floor 19 Chicago IL 60606	8904	356160.00	6115214	07/14/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/04/2016	Stock Option Exercise	Issuer			4200	07/14/2025	Cash
Common	02/20/2017	Stock Option Exercise	Issuer			4704	07/14/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Monopar Therapeutics (MNPR) shares are covered in the Form 144?

The notice covers 8,904 common shares.

What is the aggregate market value of the proposed MNPR share sale?

The filing lists an aggregate value of $356,160 for the shares to be sold.

When is the approximate sale date mentioned in the Form 144 for MNPR?

The shares are expected to be sold on or about 14 July 2025.

Which broker is designated to execute the MNPR share sale?

Merrill Lynch Pierce Fenner & Smith Inc., 110 N. Wacker Dr., Chicago, IL 60606.

How many shares of Monopar Therapeutics are outstanding according to the filing?

The Form 144 cites 6,115,214 shares outstanding.

Were any MNPR shares sold by the filer in the preceding three months?

No; the filing states "Nothing to Report" for past three-month sales.